Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Astellas Pharma Inc.
Scientific Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission